Astragaloside IV
Product Code:
CDX-A0577
CDX-A0577
Host Type:
Plant
Plant
Regulatory Status:
RUO
RUO
Shipping:
AMBIENT
AMBIENT
Storage:
Short Term: +4°C, Long Term: -20°C
Short Term: +4°C, Long Term: -20°C
No additional charges, what you see is what you pay! *
| Code | Size | Price |
|---|
| CDX-A0577-M050 | 50 mg | £224.00 |
Quantity:
| CDX-A0577-M100 | 100 mg | £364.00 |
Quantity:
Prices exclude any Taxes / VAT
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: Switzerland.
Typical lead time: 7-10 working days.
Contact us for more accurate information.
Typical lead time: 7-10 working days.
Contact us for more accurate information.
- Further Information
- Documents
- References
- Show All
Further Information
Alternate Names/Synonyms:
AS-IV; AST-IV; Astrasieversianin XIV; Cyclosieversioside F; Cyclosiversioside F; Astramembrannin I; Astragaloside A
Appearance:
White to off-white powder.
CAS:
84687-43-4
EClass:
32160000
Form (Short):
liquid
Handling Advice:
Protect from light and moisture.
InChi:
InChI=1S/C41H68O14/c1-35(2)24(54-33-29(48)26(45)20(44)17-51-33)9-11-41-18-40(41)13-12-37(5)31(39(7)10-8-25(55-39)36(3,4)50)19(43)15-38(37,6)23(40)14-21(32(35)41)52-34-30(49)28(47)27(46)22(16-42)53-34/h19-34,42-50H,8-18H2,1-7H3/t19-,20+,21-,22+,23-,24-,25-,26-,27+,28-,29+,30+,31-,32-,33+,34+,37+,38-,39+,40-,41+/m0/s1
InChiKey:
QMNWISYXSJWHRY-RXMVGYINSA-N
Long Description:
Chemical. CAS: 84687-43-4. Formula: C41H68O14. MW: 784.98. Astragaloside IV (AS-IV) is a bioactive saponin and constituent of the traditional chinese medicine plant Astragali radix. AS-IV has multiple pharmacologic effects, including anti-inflammatory, antioxidative, anti-asthma, antidiabetes, anticancer, immunoregulation, neuroprotective and cardioprotective properties via numerous signaling pathways. This includes inhibition of NF-kappaB, inducing hypoxia-inducible factor-1alpha accumulation via PI3K/Akt pathway, reducing Abeta production in Alzheimer's disease through inhibition of BACE1, working as a natural PPARgamma agonist, improving lipid metabolism in obese mice, enhancing chemosensitivity through B7-H3 inhibition, and suppressing glucose-induced NLRP3 inflammasome activation.
MDL:
MFCD16036240
Molecular Formula:
C41H68O14
Molecular Weight:
784.98
Package Type:
Vial
Product Description:
Astragaloside IV (AS-IV) is a bioactive saponin and constituent of the traditional chinese medicine plant Astragali radix. AS-IV has multiple pharmacologic effects, including anti-inflammatory, antioxidative, anti-asthma, antidiabetes, anticancer, immunoregulation, neuroprotective and cardioprotective properties via numerous signaling pathways. This includes inhibition of NF-kappaB, inducing hypoxia-inducible factor-1alpha accumulation via PI3K/Akt pathway, reducing Abeta production in Alzheimer's disease through inhibition of BACE1, working as a natural PPARgamma agonist, improving lipid metabolism in obese mice, enhancing chemosensitivity through CD276 (B7-H3)-pathway inhibition, and suppressing glucose-induced NLRP3 inflammasome activation.
Purity:
>98% (HPLC)
SMILES:
O[C@H]1C[C@@]2(C)[C@]3([H])C[C@H](O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)[C@@]5([H])C(C)(C)[C@@H](O[C@H]6OC[C@@H](O)[C@H](O)[C@H]6O)CC[C@]57[C@]3(C7)CC[C@]2(C)[C@H]1[C@]8(C)O[C@H](C(C)(O)C)CC8
Solubility Chemicals:
Soluble in DMSO (30mg/ml) or DMF (20mg/ml).
Source / Host:
Plant
Transportation:
Non-hazardous
UNSPSC Category:
Natural Products/Extracts
UNSPSC Number:
12352200
Use & Stability:
Stable for at least 2 years after receipt when stored at -20°C.
Documents
References
(1) Y.P. Wang, et al.; Acta Pharmacol. Sin. 23, 263 (2002) | (2) W.J. Zhang, et al.; Thromb. Haemost. 90, 904 (2003) | (3) M.E. Xu, et al.; Acta Pharmacol. Sin. 27, 229 (2006) | (4) W.S. Chan, et al.; Neurochem. Int. 55, 414 (2009) | (5) L. Zhang, et al.; J. Pharmacol. Exp. Ther. 338, 485 (2011) | (6) X. Chen, et al.; J. Ethnopharmacol. 139, 721 (2012) | (7) D. Gui, et al.; PLoS One 7, e39824 (2012) | (8) S. Ren, et al.; J. Tradit. Chin. Med. 33, 413 (2013) (Review) | (9) H. Wu, et al.; Sci. Rep. 6, 30190 (2016) | (10) C.S. He, et al.; Cell Physiol. Biochem. 40, 1221 (2016) | (11) X. Wang, et al.; Mol. Neurobiol. 54, 2939 (2017) | (12) L. Li, et al.; Fundam. Clin. Pharmacol. 31, 17 (2017) (Review) | (13) L. Xia, et al.; Exp. Ther. Med. 14, 5569 (2017) | (14) P. Sun, et al.; Front. Biosci. 24, 597 (2019) | (15) B. Leng, et al.; Mediators Inflamm. 2019, 1082497 (2019) | (16) Z. Zhang, et al.; Mol. Med. Rep. 20, 4612 (2019)